Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
200 stopped studies mapped to Prostate Carcinoma and descendants · 97% state a reason
Over the 200 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05437679 | Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic…(CHARTER) | — | terminated | Jun 29, 2022 | Angle plc | Futility (slow enrollment) | Efficacy / futility |
| NCT04227275 | A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Jan 13, 2020 | Tceleron Therapeutics, Inc. | Based on the safety events and evidence of biologic activity without sustained clinical responses… | Safety / toxicity |
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic… | Phase 1 / Phase 2 | terminated | Aug 5, 2022 | Tceleron Therapeutics, Inc. | Study was stopped Sponsor discretion. No patients were dosed. | Other (stated, no rule matched) |
| NCT04575766 | A Study of FT-7051 in Men With MCRPC | Phase 1 | terminated | Oct 5, 2020 | Novo Nordisk A/S | Sponsor Decision | Sponsor / business decision |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid… | Phase 1 | terminated | Sep 9, 2020 | Nuvation Bio Inc. | Sponsor decision | Sponsor / business decision |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | withdrawn | Mar 4, 2021 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT02516670 | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate… | Phase 2 | terminated | Aug 6, 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | insufficient clinical response per DSMB | Other (stated, no rule matched) |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined…(THRIP) | N/A | terminated | Jun 12, 2018 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | outdated, progress in clinical practice. | Other (stated, no rule matched) |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | Phase 3 | terminated | May 24, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study was terminated by DSMB due to futility. | Efficacy / futility |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | Phase 1 / Phase 2 | terminated | Apr 13, 2021 | Veru Inc. | Study terminated as end points were not achieved at current dose level. | Other (stated, no rule matched) |
| NCT04077021 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Sep 4, 2019 | Calibr, a division of Scripps Research | Business decision | Sponsor / business decision |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | Phase 1 | withdrawn | May 10, 2021 | Syneos Health | Study abandoned, no participants enrolled | Enrollment / accrual |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate…(CROSSBOW) | Phase 2 | terminated | Sep 11, 2019 | Sir Mortimer B. Davis - Jewish General Hospital | Drug no longer available | Other (stated, no rule matched) |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | Phase 3 | terminated | Feb 24, 2023 | Timothy Hoffman | The investigational product was approved by the FDA (12/20/2021) and is now commercially available | Other (stated, no rule matched) |
| NCT02721979 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | Phase 2 | terminated | Mar 29, 2016 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT02420652 | Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate…(PRIMA) | Phase 2 | terminated | Apr 20, 2015 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT02454517 | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or…(PALS) | N/A | terminated | May 27, 2015 | Fred Hutchinson Cancer Center | Terminated due to insufficient funding | Funding |
| NCT04928820 | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer… | Phase 2 | terminated | Jun 16, 2021 | Jonsson Comprehensive Cancer Center | slow recruitment | Enrollment / accrual |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon…(ESCALATE) | Phase 3 | terminated | Jan 23, 2020 | MANA RBM | The study was stopped due to insurmountable enrollment challenges affecting trial accrual,… | Enrollment / accrual |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant… | Phase 1 / Phase 2 | withdrawn | Oct 17, 2018 | Roswell Park Cancer Institute | lack of funding | Funding |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | Phase 1 | terminated | Aug 3, 2010 | Roswell Park Cancer Institute | no value in finding efficacy | Efficacy / futility |
| NCT04279561 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in… | Phase 1 | terminated | Feb 21, 2020 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT02419846 | Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly… | N/A | terminated | Apr 17, 2015 | Case Comprehensive Cancer Center | Unable to recruit due to COVID limitations / Funding Unavailable | COVID-19 / pandemic |
| NCT03531827 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With… | Phase 2 | terminated | May 22, 2018 | National Cancer Institute (NCI) | Study was closed for toxicity. | Safety / toxicity |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With… | Phase 1 | terminated | Nov 18, 2020 | Dizal Pharmaceuticals | Due to reasons of internal business strategy, not related to study or site conduct. | Sponsor / business decision |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | Phase 2 | withdrawn | Apr 2, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | accrual on hold | Enrollment / accrual |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | Phase 2 | terminated | Jan 9, 2020 | NanOlogy, LLC | Lack of enrollment | Enrollment / accrual |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous… | Phase 2 | terminated | Oct 19, 2018 | BeiGene | Sponsor's decision to revisit the development approach for prostate cancer. | Sponsor / business decision |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced… | Phase 1 / Phase 2 | terminated | Aug 9, 2019 | Pfizer | Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not… | Other (stated, no rule matched) |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic… | Phase 1 / Phase 2 | terminated | Oct 1, 2015 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And…(AtezoVax) | Phase 2 | withdrawn | Jul 15, 2019 | University of Utah | funding source withdrawn | Funding |
| NCT02985021 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | Phase 2 | terminated | Dec 7, 2016 | Seattle Institute for Biomedical and Clinical Research | Competing studies | Other (stated, no rule matched) |
| NCT03829930 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | Phase 1 | terminated | Feb 4, 2019 | George Washington University | Sponsor discontinued the drug | Other (stated, no rule matched) |
| NCT02853097 | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients | — | terminated | Aug 2, 2016 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT03042312 | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy(RESIST-PC) | Phase 2 | terminated | Feb 3, 2017 | Endocyte | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT03261336 | Oral Calcitriol With Ketoconazole in CRPC | Phase 2 | terminated | Aug 25, 2017 | Donald Trump, MD | can not meet enrollment | Enrollment / accrual |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | Phase 1 / Phase 2 | terminated | Nov 15, 2018 | Jiangsu HengRui Medicine Co., Ltd. | According to the available data from the trial，the sponsor determined to terminate this study. | Other (stated, no rule matched) |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic… | Phase 1 / Phase 2 | terminated | May 2, 2018 | SOTIO a.s. | insufficient accrual | Enrollment / accrual |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons. | Safety / toxicity |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant… | Phase 2 | terminated | Jul 26, 2016 | University of California, Davis | Poor accrual of subjects onto study | Enrollment / accrual |
| NCT04585932 | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the… | Phase 2 | withdrawn | Oct 14, 2020 | M.D. Anderson Cancer Center | At the request of the ad interim Department Chairman due to PI is no longer at institution. | Other (stated, no rule matched) |
| NCT03327662 | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer(CTC-STOP) | Phase 3 | terminated | Oct 31, 2017 | Institute of Cancer Research, United Kingdom | Underrecruitment | Other (stated, no rule matched) |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT04399824 | Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer | N/A | withdrawn | May 22, 2020 | Jonsson Comprehensive Cancer Center | Study did not open | Other (stated, no rule matched) |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | Phase 2 | terminated | Jun 27, 2018 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | Phase 2 | withdrawn | May 22, 2013 | Jonsson Comprehensive Cancer Center | no participants enrolled | Enrollment / accrual |
| NCT02597894 | Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing… | N/A | withdrawn | Nov 5, 2015 | Jonsson Comprehensive Cancer Center | P. I. left the Institution. Study never opened | Other (stated, no rule matched) |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and… | Phase 2 | terminated | Jun 20, 2014 | University of California, San Francisco | Funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 5, 2023source: clinicaltrials